Randa Abdelmasih
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Randa Abdelmasih has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Mustajab Hasan
Internal Medicine, University of Central Florida College of Medicine, Ocala, USA
3 shared publications- Ramy Abdelmaseih
University of Central Florida College of Medicine, Graduate Medical Education, Orlando, FL
3 shared publications - Alan Hamza
Internal Medicine, Ocala Regional Medical Center (ORMC), Ocala, USA
1 shared publication - Aneta Tarasiuk-Rusek
Infectious Disease, Ocala Regional Medical Center, University of Central Florida College of Medicine, Ocala, USA
1 shared publication - Anuj Kunadia
Internal Medicine, University of Central Florida College of Medicine, Orlando, USA
1 shared publication - Bilal Ashraf
Internal Medicine, University of Central Florida College of Medicine, Ocala, USA
1 shared publication
Latest Publications
- Open Access
- 15 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15660
Emphysematous Cholecystitis Secondary to Fusobacterium nucleatum
Fusobacterium nucleatum may be implicated in cases of emphysematous cholecystitis (EC) and carries a high mortality risk, especially in individuals with heart disease, renal insufficiency, and underlying malignancy. Fusobacterium infections are rarely detected in the setting of cholecystitis possibly due to the difficulty with properly culturing the bacteria. We describe a case of a patient with EC in whom blood cultures were positive for growth of F. nucleatum in one of two samples. The patient was treated with empiric antibiotic therapy consisting of metronidazole and cefepime. In patients with EC and negative cultures, it is possible that they may have an undetected infection with fusobacteria, which carries a high mortality risk. As such, clinicians should maintain a high degree of suspicion of obligate anaerobic infection in patients who have negative blood culture for growth in the setting of EC and consider continuation of adequate antimicrobial coverage.
- 15 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15660
Open AccessEmphysematous Cholecystitis Secondary to Fusobacterium nucleatum
Fusobacterium nucleatum may be implicated in cases of emphysematous cholecystitis (EC) and carries a high mortality risk, especially in individuals with heart disease, renal insufficiency, and underlying malignancy. Fusobacterium infections are rarely detected in the setting of cholecystitis possibly due to the difficulty with properly culturing the bacteria. We describe a case of a patient with EC in whom blood cultures were positive for growth of F. nucleatum in one of two samples. The patient was treated with empiric antibiotic therapy consisting of metronidazole and cefepime. In patients with EC and negative cultures, it is possible that they may have an undetected infection with fusobacteria, which carries a high mortality risk. As such, clinicians should maintain a high degree of suspicion of obligate anaerobic infection in patients who have negative blood culture for growth in the setting of EC and consider continuation of adequate antimicrobial coverage.
- Open Access
- 5 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15467
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.
- 5 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15467
Open AccessAtrial Fibrillation as a Possible Adverse Reaction to Evolocumab
Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.
- Open Access
- 5 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15458
Uncommon Pathogen in an Unexpected Host: A Rare Case of Rothia mucilaginosa Infective Endocarditis in an Immunocompetent Patient Without an Underlying Valvular Disease
Rothia mucilaginosa is an infrequent opportunistic pathogen that affects immunocompromised patients, with a high affinity to prosthetic devices. Infections in immunocompetent individuals are extremely rare and usually related to pre-existing valvular heart disease. We report the first case of Rothia endocarditis in an immunocompetent patient without an underlying valve disease.
- 5 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15458
Open AccessUncommon Pathogen in an Unexpected Host: A Rare Case of Rothia mucilaginosa Infective Endocarditis in an Immunocompetent Patient Without an Underlying Valvular Disease
Rothia mucilaginosa is an infrequent opportunistic pathogen that affects immunocompromised patients, with a high affinity to prosthetic devices. Infections in immunocompetent individuals are extremely rare and usually related to pre-existing valvular heart disease. We report the first case of Rothia endocarditis in an immunocompetent patient without an underlying valve disease.
- Open Access
- 28 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Southern Tick-Associated Rash Illness: Florida's Lyme Disease Variant
Southern tick-associated rash illness (STARI) is an emerging zoonotic disease causing an annular rash with central clearing that is almost identical to erythema migrans seen in Lyme disease. It is spread by Amblyomma americanum tick bite. Although it is still debatable, this zoonotic disease is thought to be caused by Borrelia lonestari spirochete. At this time, there is no approved diagnostic modality nor approved treatment for such an illness. Here we describe a rare case of STARI in a 63-year-old female and shed light on the differences between STARI and Lyme disease.
- 28 May 2021
- Published by Springer Nature in Cureus
- Vol. 13 (5)
Open AccessSouthern Tick-Associated Rash Illness: Florida's Lyme Disease Variant
Southern tick-associated rash illness (STARI) is an emerging zoonotic disease causing an annular rash with central clearing that is almost identical to erythema migrans seen in Lyme disease. It is spread by Amblyomma americanum tick bite. Although it is still debatable, this zoonotic disease is thought to be caused by Borrelia lonestari spirochete. At this time, there is no approved diagnostic modality nor approved treatment for such an illness. Here we describe a rare case of STARI in a 63-year-old female and shed light on the differences between STARI and Lyme disease.
- Open Access
- 2 June 2020
- Published by Springer Nature in Cureus
- Vol. 12 (6) , e8415
Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review
COVID-19 represents a global health crisis. Several studies are evaluating potential therapies including hydroxychloroquine (HCQ) which is given to patients based on limited observational evidence. However, it can cause serious adverse events. Moreover, recent studies showed no benefits due to HCQ. We present two COVID-19 patients treated with HCQ and had adverse events.
- 2 June 2020
- Published by Springer Nature in Cureus
- Vol. 12 (6) , e8415
Open AccessSerious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review
COVID-19 represents a global health crisis. Several studies are evaluating potential therapies including hydroxychloroquine (HCQ) which is given to patients based on limited observational evidence. However, it can cause serious adverse events. Moreover, recent studies showed no benefits due to HCQ. We present two COVID-19 patients treated with HCQ and had adverse events.